ArticleFrontiers in molecular biosciences2025
Single-cell dissection of PTM-related networks reveals an immunosuppressed osteosarcoma ecosystem.
Article in Frontiers in molecular biosciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Bone niche-driven antitumor immune failure in osteosarcoma: Mechanisms and therapeutic implications (Review).Oncology letters · 2026Review
- Development and validation of a novel prognostic and for osteosarcoma patients utilizing multiple organelle related genes.Discover oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Osteosarcoma remains lethal for many patients with metastatic or relapsed disease. Post-translational modifications (PTMs) regulate protein signaling and may shape the tumor microenvironment and clinical behavior in osteosarcoma, but PTM-anchored transcriptomic programs are as yet not well defined. Methods: We integrated single-cell RNA sequencing from GSE162454 with curated PTM and immune gene sets to build a PTM-related framework for osteosarcoma. Tumor cell differentially expressed genes were intersected with PTM and immune repertoires to derive candidates. A PTM-related prognostic score was trained in TARGET-OS and validated in GSE21257 and GSE16091. Immune infiltration and microenvironment features were profiled using ssGSEA, Estimation of STromal and Immune cells in MAlignant Tumor tissues using Expression (ESTIMATE) data, and Tumor Immune Dysfunction and Exclusion (TIDE) scores. Model interpretation used SHapley Additive exPlanations (SHAP) and single-cell localization. GRN was prioritized for exploration of immune correlations and Results: The three-way intersection yielded 298 genes. The PTM-related score stratified overall survival in training and validation cohorts and remained independent of clinical covariates. High scores aligned with an immunosuppressed, stroma-rich microenvironment, with lower ImmuneScores and ESTIMATE scores, enrichment of myeloid and regulatory lineages, higher dysfunction and exclusion by TIDE, and reduced cytolytic, interferon, and antigen-presentation programs. SHAP highlighted a compact driver set enriched in malignant and stromal compartments. GRN showed strong contribution and consistent single-cell localization. Elevated GRN correlated with plasmacytoid dendritic cells, myeloid-derived suppressor cells (MDSCs), macrophages, regulatory T cells (Tregs), and multiple inhibitory checkpoints and with diminished immune effector functions. GRN silencing reduced proliferation, clonogenicity, migration, and invasion in osteosarcoma cells. Conclusion: A PTM-anchored transcriptomic signature captures prognostic heterogeneity in osteosarcoma and links adverse outcome to an immunosuppressed microenvironment. GRN emerges as a tumor- and stroma-intrinsic mediator of immune suppression and malignant traits and represents a biologically grounded target for future mechanistic and therapeutic studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.